Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $125.9 million.

  • Northwest Biotherapeutics' Total Liabilities rose 3451.87% to $125.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.9 million, marking a year-over-year increase of 3451.87%. This contributed to the annual value of $105.7 million for FY2024, which is 4109.45% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Total Liabilities stood at $125.9 million for Q3 2025, which was up 3451.87% from $116.2 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Total Liabilities high stood at $385.7 million for Q1 2021, and its period low was $64.1 million during Q2 2023.
  • Moreover, its 5-year median value for Total Liabilities was $116.2 million (2025), whereas its average is $146.9 million.
  • In the last 5 years, Northwest Biotherapeutics' Total Liabilities soared by 77302.77% in 2021 and then tumbled by 6851.98% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Total Liabilities (Quarter) stood at $164.2 million in 2021, then fell by 16.93% to $136.4 million in 2022, then plummeted by 45.06% to $74.9 million in 2023, then surged by 41.09% to $105.7 million in 2024, then grew by 19.06% to $125.9 million in 2025.
  • Its Total Liabilities stands at $125.9 million for Q3 2025, versus $116.2 million for Q2 2025 and $112.3 million for Q1 2025.